Jonas E.
- Country
- Sweden
- Department
- Universitetssjukvården Vuxenpsykiatrin
Research Overview
- Long-Term Safety and Efficacy of Repeated Rituximab as Adjunctive Therapy in Patients with Schizophrenia Spectrum Disorders (RITS‑LONG)
- Long-term Safety Evaluation of Iclepertin in Schizophrenia Patients Post-Completion of Phase III Trials
- Randomized Controlled Trial of Rituximab Versus Placebo in Adults with Schizophrenia Spectrum Disorder
Data & Insights
Has run more than one trial at 4 of 90 partner sites.
Specializations
Psychiatric Disorders
This investigator specializes in the therapeutic management of treatment-resistant depression and schizophrenia spectrum disorders, with particular emphasis on innovative treatment approaches.
- Treatment-Resistant Depression (TRD)
- Schizophrenia
- Cognitive Impairment in Schizophrenia
The investigator focuses on evaluating novel therapeutic compounds for psychiatric conditions that have shown resistance to conventional treatments.
Therapeutic Approaches
Expertise in investigating diverse therapeutic modalities, including immunomodulatory treatments and novel psychopharmacological interventions for psychiatric disorders.
- Innovative Pharmacological Compounds
- Immunotherapy Applications
- Psychological Support Integration
The research encompasses both traditional and experimental therapeutic approaches in psychiatric care.
Clinical Outcomes
Specialized in assessing treatment efficacy through comprehensive evaluation of psychiatric symptoms and functional improvements in mental health conditions.
- Symptom Reduction Assessment
- Long-term Safety Monitoring
- Clinical Response Evaluation
Focuses on measuring therapeutic outcomes in complex psychiatric conditions using standardized assessment tools.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.